15958-69-7

Upstream product

• 129-44-2 1,5-diaminoanthraquinone 
• 100-44-7 benzyl chloride 
• 82-46-2 1,5-Dichloroanthraquinone 
• 100-46-9 benzylamine 

Relevant academic research and scientific papers

Method for catalytically synthesizing N-aryl/alkyl anthraquinone and derivatives thereof by using carbene metal ligand

The invention discloses a method for catalytically synthesizing N-aryl/alkyl anthraquinone and derivatives thereof by using a carbene metal ligand. The method for catalytically synthesizing the N-aryl/alkyl anthraquinone and the derivatives thereof by using the carbene metal ligand provided by the invention comprises the following steps: with the carbene metal ligand and alkali as catalysts and anthraquinone compounds and primary amine compounds as raw materials, allowing the anthraquinone compounds and the primary amine compounds to react in an organic solvent at 100-150 DEG C for 2-12 hours;cooling a reaction liquid after the reaction is finished, and carrying out rotary evaporation so as to remove the solvent; purifying a crude product through a silicon dioxide column, and carrying outeluting with petroleum ether/dichloromethane so as to obtain pure N-aryl/alkyl anthraquinone and derivatives thereof. According to the invention, the selectivity of a tetra-substituted target productis improved and is 90% or above; byproducts are few, and the separation cost of a product is reduced; the reaction is carried out in the organic solvent without water and oxyge;, simple reaction conditions and easy operation are achieved; and industrial production is facilitated.

Tandem organocatalysis and photocatalysis: An anthraquinone-catalyzed indole-c3-alkylation/photooxidation/1,2-shift sequence

Quinones exhibit orthogonal ground- and excited-state reactivities and are therefore highly suitable organocatalysts for the development of sequential catalytic processes. Herein, the discovery of an anthraquinone-catalyzed thermal indole-C3-alkylation with benzylamines is described, which can be combined sequentially with a new visible-light-driven catalytic photooxidation/1,2-shift reaction. The one-flask tandem process converts indoles into 3-benzylindole intermediates, which are further transformed into new fluorescent 2,2-disubstituted indoline-3-one derivatives.

Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives

This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105/mL, and the SEAP activity after 24 h at 37 □. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P0.05 is presented by an asterisk.

Structure-Based Design and Synthesis of Regioisomeric Disubstituted Aminoanthraquinone Derivatives as Potential Anticancer Agents

Continuing our ongoing studies on cytotoxic substances, we report the synthesis and cytotoxic properties of a series of symmetric 1,5-diamino-9,10-anthraquinones with potentially bioreducible groups. Symmetric amination of 1,5-dichloro-9,10-anthraquinone with the appropriate primary amines in the presence of DMF furnished the structurally related aminoanthraquinone analogs 1-19. Their in vitro cytotoxic activity was evaluated using rat glioma C6 cells, human hepatoma G2 cells, and 2.2.15 cells. Several compounds exhibited very high antitumor activities in these assays. Compound 4 efficiently inhibited C6 cells, human hepatoma G2 cells, and 2.2.15 cells, as determined by means of the XTT colorimetric assay. The antiproliferative activity of 4 was markedly enhanced, reaching a potency comparable to those of the powerful anticancer agents mitoxantrone, adriamycin, and cisplatin. Biological evaluations and structure/activity relationships within this class of novel aminoanthraquinones are discussed.